Summary & Overview
HCPCS A9500: Technetium tc-99m Sestamibi, Diagnostic, Per Study Dose
HCPCS Level II code A9500 designates a diagnostic dose of technetium tc-99m sestamibi, a radiopharmaceutical widely used in nuclear medicine for myocardial perfusion and select diagnostic imaging studies. This code matters nationally because it standardizes reporting for the radiopharmaceutical agent itself, which affects billing for diagnostic imaging workflows, inventory management, and payer coverage decisions across diverse care settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of reimbursement benchmarks and typical site-of-service patterns, a concise clinical context for why technetium tc-99m sestamibi is used, and notes on coding practice and common modifiers. The content summarizes typical utilization scenarios, contrasts outpatient and inpatient administration settings, and highlights areas where policy updates or payer-specific coverage rules commonly influence billing practices.
This summary serves clinicians, billing professionals, and policy analysts seeking a clear, national-level reference for HCPCS Level II code A9500, its clinical use, and the reimbursement landscape affecting diagnostic nuclear medicine services.
Billing Code Overview
HCPCS Level II code A9500 represents Technetium tc-99m sestamibi, diagnostic, per study dose. This billing code describes a radiopharmaceutical dose used for nuclear medicine diagnostic studies, most commonly myocardial perfusion imaging and certain oncologic or parathyroid imaging procedures.
-
Service type: Diagnostic nuclear medicine radiopharmaceutical administration
-
Typical site of service: Hospital outpatient departments, hospital inpatient nuclear medicine departments, freestanding imaging centers, and specialized nuclear medicine laboratories
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 62-year-old adult with chest pain and intermediate pre-test probability for coronary artery disease referred for myocardial perfusion imaging. The nuclear medicine department schedules a single- or dual-phase technetium tc-99m sestamibi study to evaluate for reversible ischemia. The workflow includes outpatient check-in, IV access placement, resting and/or stress imaging protocols (exercise or pharmacologic stress with agents such as regadenoson), administration of A9500 (technetium tc-99m sestamibi, per study dose) via nuclear medicine technologist under physician order, timed image acquisition with a gamma camera, image processing by the nuclear medicine physician, and issuance of a diagnostic report documenting perfusion defects, left ventricular function estimates, and recommendations for further cardiology management. Typical site of service is an outpatient hospital radiology/nuclear medicine department or freestanding imaging center; inpatient use occurs when assessing perfusion in hospitalized patients. Patient preparation includes withholding caffeine for pharmacologic stress, establishing IV access, and assessing contraindications to stress testing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier used | Rarely appended; indicates unmodified service when required by payer formats. |